← HUTCHMED (China) Ltd (HMDCF) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
HUTCHMED (China) Ltd (HMDCF)
Pharmaceutical Preparations · market cap $1.9B · as of 2026-07-15
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-12-25 (est.)
PDUFA
Pipeline
7
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
HUTCHMED (China) Ltd (HMDCF) is a ~$2.5B market-cap Hong Kong-based biotechnology company with 1,780 employees and a pipeline spanning oncology and autoimmune disease. Its lead near-term catalyst is a December 2025 PDUFA date for HMPL-523 (300mg PO QD) in Warm Antibody Autoimmune Hemolytic Anemia (wAIHA), rated with high importance (9/10). The company also has HMPL-523 in Phase 3 for Primary Immune Thrombocytopenia (ITP) and HMPL-760 in Phase 3 for relapsed/refractory DLBCL.
The catalyst path
- 2026-12-25 (est.)PDUFA · HMPL-523(300mg PO QD)imp 9/10
- 2027-09-24 (est.)PDUFA · ORPATHYS plus TAGRISSOimp 8/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| surufatinib | Phase 2 | Tumors |
| HMPL-523 | Phase 3 | Primary Immune Thrombocytopenia (ITP) |
| HMPL-A830 | Phase 2 | Solid Tumor, Adult |
| HMPL-A580 | Phase 2 | Solid Tumors, Adult |
| HMPL-760 | Phase 3 | Relapsed/Refractory Diffuse Large B-Cell Lymphoma |
| HMPL-523(300mg PO QD) | Phase 3 | Warm Antibody Autoimmune Hemolytic Anemia |
| Pamiparib | Phase 2 | Ovarian Cancer |
Price & technical context
3-month
+0.0%
6-month
-23.4%
12-month
-32.5%
52-wk range
$2.16–$3.66
vs 50-day MA
+0.0%
vs 200-day MA
-17.9%
Realized vol
31.0%
Max drawdown
-43.5%
Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for HMDCF (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 7 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.